Your browser is no longer supported. Please, upgrade your browser.
GRTS Gritstone Oncology, Inc. daily Stock Chart
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.28 Insider Own2.30% Shs Outstand30.66M Perf Week-18.46%
Market Cap755.77M Forward P/E- EPS next Y-2.46 Insider Trans- Shs Float26.93M Perf Month4.45%
Income-64.80M PEG- EPS next Q-0.59 Inst Own43.80% Short Float3.31% Perf Quarter-
Sales0.10M P/S7872.59 EPS this Y-120.70% Inst Trans- Short Ratio4.86 Perf Half Y-
Book/sh-3.62 P/B- EPS next Y- ROA- Target Price23.00 Perf Year-
Cash/sh2.52 P/C9.76 EPS next 5Y- ROE- 52W Range11.22 - 32.90 Perf YTD73.10%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-25.08% Beta-
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low119.70% ATR2.54
Employees102 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)53.10 Volatility11.38% 10.32%
OptionableNo Debt/Eq- EPS Q/Q-24.20% Profit Margin- Rel Volume0.69 Prev Close25.18
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume183.27K Price24.65
Recom2.00 SMA200.40% SMA5027.57% SMA20028.23% Volume126,665 Change-2.10%
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
Dec-10-18 07:00AM  Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead GlobeNewswire -11.37%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-14-18 08:00AM  Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals -5.55%
Sep-28-18 09:18AM  Gritstone Oncology expects to begin trading today, prices at $15 per share MarketWatch
07:24AM  [$$] Gritstone Oncology Prices Upsized IPO at Top of Range The Wall Street Journal
Sep-27-18 09:30PM  Gritstone Oncology Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Gritstone Oncology Inc. is engaged in the discovery and development of cancer immunotherapies. The company focuses on developing tumor-specific neo-antigens-based therapies for non-small cell lung cancer. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was incorporated in 2015 and is based in San Francisco, California with operations in Cambridge, Massachusetts.